person · Reporting owner

FRATES JAMES M

Disclosed activity across 3 companies

Tapewire entity: 21224
SEC CIK: 0001235598

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alkermes plc.ALKS · Entity 2392	SVP, Alks Inc; CFO ALKS	May 14, 2020	May 14, 2020
Amylyx Pharmaceuticals, Inc.AMLX · Entity 259	Chief Financial Officer	September 10, 2026	September 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alkermes plc.

Report date May 14, 2020 · Filed May 14, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	91,828	Reported balance After 2020-05-14 transaction · row 1 1 source row Row 1 · 2020-05-14 · Exercise / conversion · Acquired 21,983 · Balance 91,828
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.74 · Expires 2020-05-17	Direct	0	Reported balance After 2020-05-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-05-14 · Exercise / conversion · Disposed 21,983 · Balance 0 F3: These options are fully vested in accordance with their terms.
Ordinary SharesSEC Table I · non-derivative	IndirectBy 2018 GRAT No. 2	1,669	Reported balance Holding disclosure · report date 2020-05-14 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,669 F1: Shares held by James M. Frates 2018 Grantor Retained Annuity Trust No. 2 dated May 25, 2018 (the "2018 GRAT No. 2"). The Reporting Person is a trustee and beneficiary of the 2018 GRAT No. 2 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2018 GRAT No. 2.
Ordinary SharesSEC Table I · non-derivative	IndirectBy 2019 GRAT No. 1	150,000	Reported balance Holding disclosure · report date 2020-05-14 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 150,000 F2: Shares held by the 2019 GRAT No. 1. The Reporting Person is a trustee and beneficiary of the 2019 GRAT No. 1 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2019 GRAT No. 1.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Sons	4,000	Reported balance Holding disclosure · report date 2020-05-14 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 4,000

Filing footnotes · ownership attribution and instrument terms

F1: Shares held by James M. Frates 2018 Grantor Retained Annuity Trust No. 2 dated May 25, 2018 (the "2018 GRAT No. 2"). The Reporting Person is a trustee and beneficiary of the 2018 GRAT No. 2 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2018 GRAT No. 2.

F2: Shares held by the 2019 GRAT No. 1. The Reporting Person is a trustee and beneficiary of the 2019 GRAT No. 1 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2019 GRAT No. 1.

F3: These options are fully vested in accordance with their terms.

Amylyx Pharmaceuticals, Inc.

Report date September 10, 2026 · Filed September 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	233,625	Ending reported balance After 2026-09-10 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-10 · Sale · Disposed 9,768 · Balance 234,667 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.805 to $32.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 2 · 2026-09-10 · Sale · Disposed 1,042 · Balance 233,625 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.84 to $33.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Common StockSEC Table I · non-derivative	IndirectBy Trust	100,000	Reported balance Holding disclosure · report date 2026-09-10 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 100,000 F4: Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Trust	15,459	Reported balance Holding disclosure · report date 2026-09-10 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 15,459 F5: Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Trust	11,072	Reported balance Holding disclosure · report date 2026-09-10 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 11,072 F6: Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Trust	40,000	Reported balance Holding disclosure · report date 2026-09-10 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 40,000 F7: Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.805 to $32.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.84 to $33.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

F5: Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

F6: Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

F7: Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Sage Therapeutics, Inc.

Report date July 31, 2025 · Filed July 31, 2025

Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-07-31 transaction · row 1 1 source row Row 1 · 2025-07-31 · Other · Disposed 2,845 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.14 · Expires 2035-01-03	Direct	Reported balance After 2025-07-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-07-31 · Disposition to issuer · Disposed 19,154 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2035-06-10	Direct	Reported balance After 2025-07-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-07-31 · Disposition to issuer · Disposed 21,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes.

F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.

F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2022 Filed Jun 17, 2022 20:36 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	9,947	$0.00 Strike: $31.36	$0.00	Disclosure SEC source: 0001562180-22-005207 · primarydocument.xml · derivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,947 Underlying: Common Stock · 9,947 shares Expires 2032-06-16 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 16, 2023 or the day immediately prior to the 2023 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
February 11, 2022 Filed Mar 28, 2022 20:30 UTC	Amylyx Pharmaceuticals, Inc. AMLX · Entity 259	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $19.63	$0.00	Disclosure SEC source: 0000899243-22-012474 · doc4.xml · derivative · entry 1 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-11 F1 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document
January 06, 2022 Filed Jan 11, 2022 01:28 UTC	Amylyx Pharmaceuticals, Inc. AMLX · Entity 259	GrantStock Option (right to buy) · Derivative	142,500	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0000899243-22-001512 · doc4.xml · derivative · entry 2 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,500 Underlying: Common Stock · 142,500 shares Expires 2032-01-06 F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document
January 06, 2022 Filed Jan 11, 2022 01:28 UTC	Amylyx Pharmaceuticals, Inc. AMLX · Entity 259	GrantCommon Stock	31,667	$0.00	$0.00	Disclosure SEC source: 0000899243-22-001512 · doc4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,667 F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first anniversary of the date of the grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document
January 06, 2022 Filed Apr 26, 2023 23:34 UTC Amendment	Amylyx Pharmaceuticals, Inc. AMLX · Entity 259	ConversionSeries C-1 Preferred Stock · Derivative	19,482	$0.00	$0.00	Disclosure SEC source: 0000899243-23-011781 · doc4a.xml · derivative · entry 2 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 19,482 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date. F1 · kind: Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date. F2 · kind: This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the "Original Form 4") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4. F1 · shares: Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date. F2 · shares: This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the "Original Form 4") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date. F2 · derivative.underlying_shares: This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the "Original Form 4") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4. F3 · ownership.nature: Shares held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document
January 06, 2022 Filed Apr 26, 2023 23:34 UTC Amendment	Amylyx Pharmaceuticals, Inc. AMLX · Entity 259	ConversionCommon Stock	19,482	$0.00	$0.00	Disclosure SEC source: 0000899243-23-011781 · doc4a.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 19,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date. F2 · kind: This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the "Original Form 4") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4. F1 · shares: Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date. F2 · shares: This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the "Original Form 4") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4. F1 · balance_after: Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date. F2 · balance_after: This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the "Original Form 4") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4. F3 · ownership.nature: Shares held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document
June 16, 2021 Filed Jun 17, 2021 20:04 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	PurchaseCommon Stock	1,810	$55.10	$99,734.62	Disclosure SEC source: 0001562180-21-004347 · primarydocument.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote 2 Disclosed balance after: 1,810 F1 · price: This transaction was executed in multiple trades at prices ranging from $55.08 USD to $55.11 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Represents 905 shares held directly by the John A. Frates 2013 Irrevocable Trust, dated December 19, 2013, and 905 shares held directly by the Peter E. Frates 2013 Irrevocable Trust, dated December 19, 2013. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
June 10, 2021 Filed Jun 11, 2021 20:11 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $76.09	$0.00	Disclosure SEC source: 0001562180-21-004210 · primarydocument.xml · derivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 10, 2022 or the day immediately prior to the 2022 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
June 09, 2020 Filed Jun 11, 2020 20:18 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $36.47	$0.00	Disclosure SEC source: 0001562180-20-004427 · primarydocument.xml · derivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 9, 2021 or the day immediately prior to the 2021 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
May 14, 2020 Filed May 14, 2020 20:58 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	21,983	$0.00 Strike: $11.74	$0.00	Disclosure SEC source: 0001127602-20-016615 · form4.xml · derivative · entry 5 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,983 shares Expires 2020-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
May 14, 2020 Filed May 14, 2020 20:58 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	21,983	$11.74	$258,080.42	Disclosure SEC source: 0001127602-20-016615 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2020 Filed Mar 3, 2020 21:27 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	4,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-20-008995 · form4.xml · derivative · entry 6 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. Read SEC document
March 01, 2020 Filed Mar 3, 2020 21:27 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,323	$20.84	$27,571.32	Disclosure SEC source: 0001127602-20-008995 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,845 Read SEC document
March 01, 2020 Filed Mar 3, 2020 21:27 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	4,500	$0.00	$0.00	Disclosure SEC source: 0001127602-20-008995 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 21, 2020 Filed Feb 24, 2020 21:11 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	5,825	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-20-007180 · form4.xml · derivative · entry 8 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,475 Underlying: Ordinary Shares · 5,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020. F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020. Read SEC document
February 21, 2020 Filed Feb 24, 2020 21:11 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,712	$20.24	$34,650.88	Disclosure SEC source: 0001127602-20-007180 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,668 Read SEC document
February 21, 2020 Filed Feb 24, 2020 21:11 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	5,825	$0.00	$0.00	Disclosure SEC source: 0001127602-20-007180 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 20, 2020 Filed Feb 24, 2020 21:11 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	24,474	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-20-007180 · form4.xml · derivative · entry 7 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,474 Underlying: Ordinary Shares · 24,474 shares Expires not disclosed F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/20/2021. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/20/2021. Read SEC document
February 20, 2020 Filed Feb 24, 2020 21:11 UTC	Alkermes plc. ALKS · Entity 2392	GrantEmployee Stock Option (Right to Buy) · Derivative	102,337	$0.00 Strike: $20.43	$0.00	Disclosure SEC source: 0001127602-20-007180 · form4.xml · derivative · entry 6 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,337 Underlying: Ordinary Shares · 102,337 shares Expires 2030-02-20 F3 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/20/2021. Read SEC document
February 17, 2020 Filed Feb 18, 2020 21:07 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	3,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-20-006015 · form4.xml · derivative · entry 9 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Ordinary Shares · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. Read SEC document
February 17, 2020 Filed Feb 18, 2020 21:07 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	904	$17.77	$16,064.08	Disclosure SEC source: 0001127602-20-006015 · form4.xml · nonDerivative · entry 4 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,555 Read SEC document
February 17, 2020 Filed Feb 18, 2020 21:07 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	3,000	$0.00	$0.00	Disclosure SEC source: 0001127602-20-006015 · form4.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 16, 2020 Filed Feb 18, 2020 21:07 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	3,375	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-20-006015 · form4.xml · derivative · entry 8 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Ordinary Shares · 3,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. Read SEC document
February 16, 2020 Filed Feb 18, 2020 21:07 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,172	$17.77	$20,826.44	Disclosure SEC source: 0001127602-20-006015 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,459 Read SEC document
February 16, 2020 Filed Feb 18, 2020 21:07 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	3,375	$0.00	$0.00	Disclosure SEC source: 0001127602-20-006015 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 13, 2019 Filed Sep 17, 2019 23:06 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $11.74	$0.00	Disclosure SEC source: 0001127602-19-028600 · form4.xml · derivative · entry 6 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,983 Underlying: Ordinary Shares · 20,000 shares Expires 2020-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
September 13, 2019 Filed Sep 17, 2019 23:06 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	20,000	$11.74	$234,800.00	Disclosure SEC source: 0001127602-19-028600 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 29, 2019 Filed Feb 4, 2020 23:02 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	1,500	$0.00	$0.00	Disclosure SEC source: 0001562180-20-000855 · primarydocument.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035 F1 · balance_after: Reflects the amount of securities beneficially owned by the reporting person as of December 31, 2019, which reflects a gift of 1,500 shares by the reporting person on August 29, 2019. Read SEC document
August 15, 2019 Filed Aug 16, 2019 20:04 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	8,000	$0.00 Strike: $28.35	$0.00	Disclosure SEC source: 0001562180-19-004305 · primarydocument.xml · derivative · entry 5 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,922 Underlying: Common Stock · 8,000 shares Expires 2026-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan and has vested in full on June 22, 2017. Read SEC document
August 15, 2019 Filed Aug 16, 2019 20:04 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	8,000	$160.58	$1,284,640.00	Disclosure SEC source: 0001562180-19-004305 · primarydocument.xml · nonDerivative · entry 4 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,535 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
August 15, 2019 Filed Aug 16, 2019 20:04 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	8,000	$28.35	$226,800.00	Disclosure SEC source: 0001562180-19-004305 · primarydocument.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 05, 2019 Filed Jun 6, 2019 20:02 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $177.41	$0.00	Disclosure SEC source: 0001562180-19-003391 · primarydocument.xml · derivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 5, 2020 or the day immediately prior to the 2020 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
May 06, 2019 Filed May 6, 2019 22:21 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	8,000	$0.00 Strike: $8.92	$0.00	Disclosure SEC source: 0001562180-19-002643 · primarydocument.xml · derivative · entry 3 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,309 Underlying: Common Stock · 8,000 shares Expires 2024-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested 33% on the first anniversary of the grant date and quarterly thereafter, such that 100% of the shares subject to the option were fully vested and exercisable on May 26, 2017. Read SEC document
May 06, 2019 Filed May 6, 2019 22:21 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	8,000	$162.22	$1,297,760.00	Disclosure SEC source: 0001562180-19-002643 · primarydocument.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,235 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
May 06, 2019 Filed May 6, 2019 22:21 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	8,000	$8.92	$71,360.00	Disclosure SEC source: 0001562180-19-002643 · primarydocument.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 06, 2019 Filed Aug 16, 2019 20:04 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	500	$0.00	$0.00	Disclosure SEC source: 0001562180-19-004305 · primarydocument.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,535 Read SEC document
May 06, 2019 Filed Aug 16, 2019 20:04 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	1,200	$0.00	$0.00	Disclosure SEC source: 0001562180-19-004305 · primarydocument.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,035 Read SEC document
March 01, 2019 Filed Mar 4, 2019 22:35 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	4,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-19-009651 · form4.xml · derivative · entry 7 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Ordinary Shares · 4,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. Read SEC document
March 01, 2019 Filed Mar 4, 2019 22:35 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,323	$34.44	$45,564.12	Disclosure SEC source: 0001127602-19-009651 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,721 Read SEC document
March 01, 2019 Filed Mar 4, 2019 22:35 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	4,500	$0.00	$0.00	Disclosure SEC source: 0001127602-19-009651 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 26, 2019 Filed Feb 27, 2019 22:12 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	2,625	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-19-008739 · form4.xml · derivative · entry 7 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This RSU award is fully vested in accordance with its terms. F4 · derivative.expiration_date: This RSU award is fully vested in accordance with its terms. Read SEC document
February 26, 2019 Filed Feb 27, 2019 22:12 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	772	$33.92	$26,186.24	Disclosure SEC source: 0001127602-19-008739 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,544 Read SEC document
February 26, 2019 Filed Feb 27, 2019 22:12 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	2,625	$0.00	$0.00	Disclosure SEC source: 0001127602-19-008739 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 21, 2019 Filed Feb 25, 2019 22:13 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	23,300	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-19-008091 · form4.xml · derivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,300 Underlying: Ordinary Shares · 23,300 shares Expires not disclosed F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020. Read SEC document
February 21, 2019 Filed Feb 25, 2019 22:13 UTC	Alkermes plc. ALKS · Entity 2392	GrantEmployee Stock Option (Right to Buy) · Derivative	90,600	$0.00 Strike: $32.57	$0.00	Disclosure SEC source: 0001127602-19-008091 · form4.xml · derivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,600 Underlying: Ordinary Shares · 90,600 shares Expires 2029-02-21 F1 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/21/2020. Read SEC document
February 17, 2019 Filed Feb 19, 2019 23:53 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	3,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-19-006969 · form4.xml · derivative · entry 10 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. Read SEC document
February 17, 2019 Filed Feb 19, 2019 23:53 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	875	$32.54	$28,472.50	Disclosure SEC source: 0001127602-19-006969 · form4.xml · nonDerivative · entry 4 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,691 Read SEC document
February 17, 2019 Filed Feb 19, 2019 23:53 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	3,000	$0.00	$0.00	Disclosure SEC source: 0001127602-19-006969 · form4.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 16, 2019 Filed Feb 19, 2019 23:53 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	3,375	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-19-006969 · form4.xml · derivative · entry 9 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 Underlying: Ordinary Shares · 3,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. Read SEC document
February 16, 2019 Filed Feb 19, 2019 23:53 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,098	$32.54	$35,728.92	Disclosure SEC source: 0001127602-19-006969 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,566 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.